Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
459.90 | 16,612 Cr | 39.65 | 2.79 | 0.22 | 7.04 | 6.41 | 3.15 | ||
1330.75 | 15,150 Cr | 89.06 | 4.59 | 0.00 | 5.10 | 7.68 | 2.77 | ||
1135.80 | 15,109 Cr | 68.84 | 6.15 | 0.00 | 8.94 | 10.61 | 6.86 | ||
3418.00 | 14,785 Cr | 35.19 | 3.74 | 0.59 | 10.62 | 14.23 | 4.98 | ||
4754.10 | 14,560 Cr | 34.91 | 5.46 | 0.23 | 15.65 | 20.00 | 13.91 | ||
1306.85 | 13,523 Cr | 30.47 | 4.28 | 0.65 | 14.03 | 18.72 | 12.36 | ||
3251.50 | 12,655 Cr | 38.64 | 8.96 | 0.31 | 23.19 | 21.43 | 9.99 | ||
| Median: 7 Co. | — | 1330.75 | 14,785 Cr | 38.64 | 4.59 | 0.23 | 10.62 | 14.23 | 6.86 |
Anupam Rasayan India Ltd (ANURAS) is currently trading at 1,313.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers. Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility. Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk. The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials. Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹1,031.75 and a high of ₹1,415.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anupam Rasayan India Ltd has a market capitalization of approximately 15,150.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anupam Rasayan India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 89.06 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 15,150.36 Cr, Anupam Rasayan India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anupam Rasayan India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 89.06. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Q4 FY26 consolidated net sales were Rs 635.78 crore (up 27.12% YoY) and net profit was Rs 42.65 crore (down 4.31% YoY).
Q4 FY26 revenue was ₹639.15 crore and net income was ₹42.65 crore, compared with ₹505.70 crore revenue and ₹44.57 crore net income in Q4 FY25.
The company reported consolidated net profit of about ₹61 crore for Q3FY26; detailed numbers in the provided data show PAT at ₹60.59 crore.
The board approved acquisition of up to 74.20% equity shares and control of Bliss GVS Pharma Limited.
Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers.
Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility.
Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk.
The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials.
Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.
Chemicals & Petrochemicals
Specialty Chemicals
14,952 Cr
Low Risk
87.9
43.0
1.9
4.6
1,415.40
1,031.75
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
2
Neutral
7
Bullish
5
Bearish
25
Neutral
7
Bullish
14
Bearish
23
Neutral
0
Bullish
9
Credit Rating Update
India Ratings & Research updated Anupam Rasayan India Ltd.'s ratings to IND AA- with Rating Watch with Negative Implications for the issuer, bank facilities and NCDs; bank limits adjusted (INR 7,275m reduced from INR 11,961m) and new assignments cover INR 8,880m (bank) and INR 1,600m (NCD).
Credit Rating Update
CRISIL has placed Anupam Rasayan's long‑ and short‑term ratings on 'Watch Developing', assigned Crisil A+ to Rs160cr NCDs and increased rated bank facilities to Rs1,620cr; watch follows proposed Bliss GVS stake acquisition that may require ~Rs300cr debt.
Credit Rating Update
Crisil has placed Anupam Rasayan's long‑term (A+) and short‑term (A1) ratings on 'Watch Developing', assigned A+ to Rs160Cr NCDs and rated bank facilities at Rs1,620Cr (enhanced), citing uncertainty around Bliss GVS acquisition funding.
Promoter pledge
On 01‑Jun‑2026 promoter Anand Sureshbhai Desai disclosed creation of a pledge/encumbrance on 3,150,000 equity shares of Anupam Rasayan India Ltd to BSE and NSE under Reg.31(1)/(2) of SEBI (SAST) Regulations.
Promoter Pledge
Anand Sureshbhai Desai (promoter) disclosed creation of a pledge/encumbrance on 3,150,000 equity shares of Anupam Rasayan India Ltd to BSE/NSE on June 1, 2026.
Open Offer / Takeover
Anupam Rasayan India Ltd published the Detailed Public Statement for an open offer to acquire up to 2,77,26,848 equity shares (26% of expanded voting capital) of Bliss GVS Pharma; DPS managed by SBI Capital Markets.
